Long-Acting GLP-1/Glucagon Receptor Agonist Fast Tracked for MASH – Renal and Urology News
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
Researchers describe feasibility and acceptability results of a quality improvement project aimed at increasing referrals to exercise for patients undergoing cancer treatment. A clinical workflow…
In this interview, Mary-Ellen Taplin, MD, discusses disparities in prostate cancer care and a unique initiative aiming to alleviate those disparities.
Ruchika Talwar hosts Yash Shah and Mihir Shah, a urologist from Jefferson in Philadelphia. They delve into their innovative research on the Utility of Artificial…
“Along those lines, we’ve taken away the traditional step therapy that has dictated overactive bladder care for quite some time,” says Ariana L. Smith, MD,…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
FDA approval of the APOL1-targeting treatment inaxaplin is highly anticipated.
bladder cancer (BC), neoadjuvant chemotherapy after radical cystectomy (RC), gemcitabine/cisplatin, MVAC/dose-dense MVAC, gemcitabine/carboplatin, circulating tumor DNA.
“Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk…
“In our commercial all-comers cohort of patients undergoing Aquablation, efficacy was similar to and safety was improved compared to the WATER I and WATER II…
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…